Publications by authors named "Jin-Kai Feng"
Background: Microvascular invasion (MVI) is a critical prognostic factor affecting long-term survival in patients with hepatocellular carcinoma (HCC). Despite its clinical significance, the optimal postoperative adjuvant therapy for HCC patients with MVI remains undefined. This study aimed to evaluate the efficacy and safety of postoperative adjuvant transarterial chemoembolization (PA-TACE) combined with lenvatinib vs PA-TACE alone in HCC patients with MVI.
View Article and Find Full Text PDFPurpose: To investigate the influence of postoperative adjuvant transarterial chemoembolization (PA-TACE) on the prognosis of hepatocellular carcinoma (HCC) patients with microvascular invasion (MVI) following liver resection (LR), and explore whether grading risk of MVI can impact the survival of HCC patients undergoing PA-TACE.
Methods: Patients who had HCC with MVI were consecutively enrolled. Overall survival (OS) and recurrence-free survival (RFS) were compared between the PA-TACE and LR groups.
Trajectories of postoperative hepatitis B virus (HBV) DNA and HBV-related hepatocellular carcinoma outcomes.
Eur J Surg Oncol
February 2025
Background: Preoperative hepatitis B virus (HBV) DNA level has been shown to correlate with the prognosis of patients with HBV-associated hepatocellular carcinoma (HCC) following liver resection, but its dynamic changes have not been reported. The aim of this longitudinal multicenter retrospective observational study was to describe the trajectory of HBV DNA after R0 liver resection in patients receiving antiviral therapy and to investigate its impact on clinical outcomes.
Methods: This study included patients with HBV-related HCC from nine hospitals in China who received antiviral therapy and R0 hepatectomy between 2015 and 2016.
Article Synopsis
- Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths globally, and the enzyme CAD plays a significant role in its development, although its specific function in HCC was previously unclear.
- Analysis of data from 424 HCC cases showed that high CAD levels correlate with poor patient prognosis and are linked to immune response dynamics, indicating that CAD levels can influence treatment sensitivity to certain therapies.
- Further experiments revealed that knocking down CAD reduced HCC cell growth and migration, suggesting that CAD acts as an oncogene in HCC progression and could serve as a valuable target for future treatments.
Background: This study aimed to compare the survival outcomes of patients with initially unresectable hepatocellular carcinoma (HCC) and portal vein tumor thrombus (PVTT) who underwent or did not undergo salvage surgery followed by a triple combination conversion treatment consisted of locoregional treatment (LRT), tyrosine kinase inhibitors (TKIs), and anti-PD-1 antibodies.
Methods: The data from 93 consecutive patients with initially unresectable HCC and PVTT across 4 medical centers were retrospectively reviewed. They were converted successfully by the triple combination treatment and underwent or did not undergo salvage resection.
Article Synopsis
- Hepatocellular carcinoma (HCC) is a common cancer worldwide, and this study explores the relationship between a specific type of cell death called disulfidptosis and long non-coding RNAs (lncRNAs) in HCC to find new biomarkers for immune response and prognosis.
- The research integrated transcriptomic data from The Cancer Genome Atlas (TCGA) to identify disulfidptosis-associated lncRNAs and created a predictive model using advanced statistical analyses, which was then tested for its effectiveness in understanding immune response and drug sensitivity.
- The resulting model identified four key lncRNAs with strong diagnostic potential for HCC, suggesting that it could help personalize immunotherapy and improve treatment decisions for patients by considering their
Preoperative and Prognostic Prediction of Microvascular Invasion in Hepatocellular Carcinoma: A Review Based on Artificial Intelligence.
Technol Cancer Res Treat
November 2023
Microvascular invasion of hepatocellular carcinoma is an important factor affecting tumor recurrence after liver resection and liver transplantation. There are many ways to classify microvascular invasion, however, an international consensus is urgently needed. Recently, artificial intelligence has emerged as an important tool for improving the clinical management of hepatocellular carcinoma.
View Article and Find Full Text PDFBackground: The use of Anti-PD-1 therapy has yielded promising outcomes in hepatocellular carcinoma (HCC). However, limited research has been conducted on the overall survival (OS) of patients with varying tumor responses and treatment duration.
Methods: This retrospective study analyzed HCC patients who received sintilimab between January 2019 and December 2020 at four centers in China.
Article Synopsis
- The study aimed to compare the survival outcomes between patients with HBV-related hepatocellular carcinoma (HCC) and portal vein tumor thrombus (PVTT) who received postoperative aspirin and those who had surgery alone.
- It involved 80 patients divided into two groups: one receiving adjuvant aspirin after surgery and the other having only the surgical procedure.
- Results showed that while overall survival rates were similar, the group taking aspirin had a significantly longer time before recurrence of PVTT, suggesting that aspirin may provide additional benefits post-surgery.
Objective: To profile the serum metabolites and metabolic pathways in colorectal cancer (CRC) patients associated with spleen-deficiency and qi-stagnation syndrome (SDQSS) or damp-heat syndrome (DHS).
Methods: From May 2020 to January 2021, CRC patients diagnosed with traditional Chinese medicine (TCM) syndromes of SDQSS or DHS were enrolled. The clinicopathological data of the SDQSS and DHS groups were compared.
Background: Immune-checkpoint inhibitors (ICIs) have revolutionized the treatment of hepatocellular carcinoma (HCC). However, long-term survival outcomes and treatment response of HCC patients undergoing immunotherapy is unpredictable. The study aimed to evaluate the role of alpha-fetoprotein (AFP) combined with neutrophil-to-lymphocyte ratio (NLR) to predict the prognosis and treatment response of HCC patients receiving ICIs.
View Article and Find Full Text PDFBackground: Immune checkpoint inhibitor (ICI), coupled with systemic chemotherapy, may enhance the clinical benefit of cancer by potentiating antitumor immunity, but its efficacy and safety are not clear in advanced intrahepatic cholangiocarcinoma (ICC). This study aims to assess the efficacy and safety of camrelizumab plus gemcitabine and oxaliplatin (GEMOX) for the treatment of advanced ICC in the real world.
Methods: Advanced ICC patients receiving at least one session of camrelizumab plus GEMOX combination treatment from March 2020 to February 2022 at two high-volume centers were considered eligible.
Purpose: This study aimed at analyzing and comparing the perioperative results and long-term oncological outcomes of hepatocellular carcinoma (HCC) patients with type 2 diabetes mellitus (T2DM) treated with laparoscopic (LLR) versus open liver resection (OLR).
Methods: Clinicopathological data of HCC patients with T2DM who underwent LLR or OLR as initial treatment from four medical centers were retrospectively reviewed. The survival outcomes of patients who underwent laparoscopic liver resection (LLR) were compared with those of patients who underwent open liver resection (OLR).
Article Synopsis
- A study was conducted to compare the effectiveness and safety of three treatment options for unresectable recurrent hepatocellular carcinoma (HCC): transarterial chemoembolization combined with lenvatinib and PD-1 inhibitors (T-L-P), TACE with lenvatinib (T-L), and TACE alone.
- Among 204 patients analyzed, those in the T-L-P group had the best survival outcomes and disease control rates compared to the other two groups.
- The study concluded that the T-L-P regimen is both safe and significantly better in enhancing survival for patients dealing with unresectable recurrent HCC.
Article Synopsis
- Early and late recurrence of hepatocellular carcinoma (HCC) shows different outcomes, and determining the early recurrence timeframe is crucial, particularly for patients with microvascular invasion (MVI).
- The study analyzed 292 patients to establish the early recurrence interval and confirmed the results with an additional 421 patients using survival analysis techniques, identifying MVI as a significant risk factor.
- Findings suggest that for HCC patients with MVI, a 13-month period post-surgery is a practical early recurrence cutoff, and adjuvant TACE treatment during this time can improve survival rates compared to surgery alone.
Background: is reportedly the best source of traditional natural bioactive constituents. Ganoderma triterpenoids (GTs) have been verified as an alternative adjuvant for treating leukemia, cancer, hepatitis and diabetes. One of the major triterpenoids, Resinacein S, has been found to regulate lipid metabolism and mitochondrial biogenesis.
View Article and Find Full Text PDFBackground: The effect of type 2 diabetes mellitus (T2DM) on survival of patients with hepatocellular carcinoma (HCC) after laparoscopic liver resection (LLR) has not been reported. This study aimed to explore the relationship between preoperative T2DM and long-term prognosis in HCC patients undergoing LLR.
Methods: HCC patients receiving LLR as initial treatment at four cancer centers were retrospectively included in this study.
Background: Portal vein tumour thrombus (PVTT) in patients with hepatocellular carcinoma (HCC) is known as a major complication associated with poor survival. We clinically defined a new and rare type of HCC, PVTT-type HCC (PVTT-HCC), in a small group of HCC patients with HCC presenting only as PVTT without a demonstrable parenchyma tumour. The clinicopathological and biological features of PVTT-HCC are not clear.
View Article and Find Full Text PDFArticle Synopsis
- - The study evaluated a combined treatment approach for patients with unresectable hepatocellular carcinoma (HCC) and portal vein tumor thrombus (PVTT), using transarterial chemoembolization (TACE), antiangiogenic therapy, and PD-1 inhibitors.
- - Results from 39 patients showed an objective response rate of 35.9% and a disease control rate of 74.4%, with median overall survival at 14 months and progression-free survival at 9.2 months.
- - Most patients (87.2%) experienced treatment-related adverse events, primarily hypertension and decreased albumin levels, but there were no treatment-related deaths in this cohort.
Purpose: To analyze the long-term oncological outcomes of Barcelona Clinic Liver Cancer (BCLC) stages 0-A hepatocellular carcinoma (HCC) patients associated with or without microvascular invasion (MVI) treated with laparoscopic versus laparotomic liver resection.
Methods: Clinicopathological data of HCC patients with BCLC stages 0-A from four medical centers were retrospectively reviewed. The survival outcomes of patients who underwent laparoscopic hepatectomy were compared with those who underwent laparotomic hepatectomy.
Article Synopsis
- The study compares the efficacy of two treatments for hepatocellular carcinoma (HCC): transarterial chemoembolization (TACE) combined with a PD-1 inhibitor versus TACE combined with a PD-1 inhibitor and lenvatinib.
- Results indicated that patients receiving the triple therapy had significantly better progression-free survival (PFS) and overall survival (OS) compared to those on the double therapy.
- While the triple therapy showed better clinical outcomes, it also had common treatment-related adverse events like decreased albumin and platelet count, but these were manageable.
Background: Patients with hepatocellular carcinoma (HCC) bile duct tumor thrombus (BDTT) have a high rate of postoperative recurrence. We aimed to describe the patterns and kinetics of recurrence in BDTT patients and provide management options accordingly.
Methods: This retrospective study included 311 HCC patients with BDTT who underwent surgery from 2009 to 2017 at five centers in China.